These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 34731403)

  • 1. Efficacy and safety of rivaroxaban in cerebral venous thrombosis: insights from a prospective cohort study.
    Pan L; Wang M; Zhou D; Ding Y; Ji X; Meng R
    J Thromb Thrombolysis; 2022 Apr; 53(3):594-600. PubMed ID: 34731403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
    Ferro JM; Coutinho JM; Dentali F; Kobayashi A; Alasheev A; Canhão P; Karpov D; Nagel S; Posthuma L; Roriz JM; Caria J; Frässdorf M; Huisman H; Reilly P; Diener HC;
    JAMA Neurol; 2019 Dec; 76(12):1457-1465. PubMed ID: 31479105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for the treatment of cerebral venous thrombosis.
    Esmaeili S; Abolmaali M; Aarabi S; Motamed MR; Chaibakhsh S; Joghataei MT; Mojtahed M; Mirzaasgari Z
    BMC Neurol; 2021 Feb; 21(1):73. PubMed ID: 33588777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.
    Yaghi S; Shu L; Bakradze E; Salehi Omran S; Giles JA; Amar JY; Henninger N; Elnazeir M; Liberman AL; Moncrieffe K; Lu J; Sharma R; Cheng Y; Zubair AS; Simpkins AN; Li GT; Kung JC; Perez D; Heldner M; Scutelnic A; Seiffge D; Siepen B; Rothstein A; Khazaal O; Do D; Kasab SA; Rahman LA; Mistry EA; Kerrigan D; Lafever H; Nguyen TN; Klein P; Aparicio H; Frontera J; Kuohn L; Agarwal S; Stretz C; Kala N; El Jamal S; Chang A; Cutting S; Xiao H; de Havenon A; Muddasani V; Wu T; Wilson D; Nouh A; Asad SD; Qureshi A; Moore J; Khatri P; Aziz Y; Casteigne B; Khan M; Cheng Y; Mac Grory B; Weiss M; Ryan D; Vedovati MC; Paciaroni M; Siegler JE; Kamen S; Yu S; Leon Guerrero CR; Atallah E; De Marchis GM; Brehm A; Dittrich T; Psychogios M; Alvarado-Dyer R; Kass-Hout T; Prabhakaran S; Honda T; Liebeskind DS; Furie K
    Stroke; 2022 Mar; 53(3):728-738. PubMed ID: 35143325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
    Field TS; Dizonno V; Almekhlafi MA; Bala F; Alhabli I; Wong H; Norena M; Villaluna MK; King-Azote P; Ratnaweera N; Mancini S; Van Gaal SC; Wilson LK; Graham BR; Sposato LA; Blacquiere D; Dewar BM; Boulos MI; Buck BH; Odier C; Perera KS; Pikula A; Tkach A; Medvedev G; Canfield C; Mortenson WB; Nadeau JO; Alshimemeri S; Benavente OR; Demchuk AM; Dowlatshahi D; Lanthier S; Lee AYY; Mandzia J; Suryanarayan D; Weitz JI; Hill MD;
    Stroke; 2023 Nov; 54(11):2724-2736. PubMed ID: 37675613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): An open-label, randomized controlled trial.
    Ma H; Gu Y; Bian T; Song H; Liu Z; Ji X; Duan J
    Int J Stroke; 2024 Jul; 19(6):635-644. PubMed ID: 38353219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Dose of Rivaroxaban Versus Warfarin for the Treatment of Isolated Calf Muscle Vein Thrombosis: A Retrospective Propensity Score-Matched Analysis.
    Qiu YH; Yang Z; Yang FJ; Su X; Chen BC; Ni HZ
    Ann Vasc Surg; 2024 Nov; 108():508-518. PubMed ID: 39025209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of oral rivaroxaban in cerebral venous thrombosis.
    Maqsood M; Imran Hasan Khan M; Yameen M; Aziz Ahmed K; Hussain N; Hussain S
    J Drug Assess; 2020 Dec; 10(1):1-6. PubMed ID: 33391859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety Assessment of Rivaroxaban for the Treatment of Cerebral Venous Sinus Thrombosis in a Chinese Population.
    Jiang YY; Chen LJ; Wu XJ; Zhou GQ; Mo DC; Li XL; Liu LY; Li JL; Luo M
    Clin Appl Thromb Hemost; 2022; 28():10760296221144038. PubMed ID: 36503260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis.
    Giles JA; Balasetti VKS; Zazulia AR
    Neurocrit Care; 2021 Dec; 35(3):783-788. PubMed ID: 34046861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin - propensity score matching study.
    Ramos-Isaza E; Tuta-Quintero E; Bastidas-Goyes A; Diaz-Quijano D; Aponte-Murcia C; Espitia-Angel J; Pinto-Beltran D; Rincón-Hernández J; Sánchez-Cuellar J; Pérez-Bueno J; Giraldo-Cadavid LF
    BMC Pharmacol Toxicol; 2023 Dec; 24(1):77. PubMed ID: 38093310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis.
    Hanafy AS; Abd-Elsalam S; Dawoud MM
    Vascul Pharmacol; 2019 Feb; 113():86-91. PubMed ID: 29886103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).
    Connor P; Sánchez van Kammen M; Lensing AWA; Chalmers E; Kállay K; Hege K; Simioni P; Biss T; Bajolle F; Bonnet D; Grunt S; Kumar R; Lvova O; Bhat R; Van Damme A; Palumbo J; Santamaria A; Saracco P; Payne J; Baird S; Godder K; Labarque V; Male C; Martinelli I; Morales Soto M; Motwani J; Shah S; Hooimeijer HL; Prins MH; Kubitza D; Smith WT; Berkowitz SD; Pap AF; Majumder M; Monagle P; Coutinho JM
    Blood Adv; 2020 Dec; 4(24):6250-6258. PubMed ID: 33351120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis.
    Ferro JM; Bendszus M; Jansen O; Coutinho JM; Dentali F; Kobayashi A; Aguiar de Sousa D; Neto LL; Miede C; Caria J; Huisman H; Diener HC;
    Int J Stroke; 2022 Feb; 17(2):189-197. PubMed ID: 33724104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recanalization of lower-limb deep veins as an index of efficacy of treatment for acute venous thrombosis].
    Kuznetsov MR; Sapelkin SV; Boldin BV; Leont'ev SG; Neskhodimov LA
    Angiol Sosud Khir; 2016; 22(3):82-8. PubMed ID: 27626254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of fixed-dose enoxaparin and adjusted-dose unfractionated heparin in patients with cerebral venous thrombosis.
    Korathanakhun P; Petpichetchian C; Petpichetchian W; Sathirapanya P
    Clin Neurol Neurosurg; 2017 Aug; 159():50-54. PubMed ID: 28535419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.